Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of HKI-272 in advanced breast cancer
2005-003098-26Phase 2Completed
- Sponsor
- Wyeth
- Start
- Feb 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of neratinib in breast cancer (2 cohorts), sponsored by Wyeth. Primary endpoint: 16-week progression-free survival rate. Started Feb 2006; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-003098-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003098-26.